Interestingly, it has been reported that inhibitors of galectin-3 function (β-lactose, a dominant-negative form of galectin-3, Gal-3C and anti-galectin-3 antibody M3/38) or revacept prevented platelet-dependent COX-2 overexpression in cancer cells [18]. Here, LGALS3 is linked to cancer.